Adverse events will be closely watched when full data are reported.

Degraders of CDK2 and KRAS follow the group's attempts at inhibiting these targets.

Regeneron is facing two FDA decisions for its T-cell engagers.

The Avanzar study could read out shortly.

The company reckons its immunotherapy could improve on Keytruda.

First-in-human studies include a new pan-KRAS inhibitor and CDK2/4 degrader.